Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

Kimmie Ng; Jeffrey A. Meyerhardt; Andrew T. Chan; Kaori Sato; Jennifer A. Chan; Donna Niedzwiecki; Leonard B. Saltz; Robert J. Mayer; Al B. Benson; Paul L. Schaefer; Renaud Whittom; Alexander Hantel; Richard M. Goldberg; Alan P. Venook; Shuji Ogino; Edward L. Giovannucci; Charles S. Fuchs

doi:10.1093/jnci/dju345

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

Kimmie Ng^*, Jeffrey A. Meyerhardt, Andrew T. Chan, Kaori Sato, Jennifer A. Chan, Donna Niedzwiecki, Leonard B. Saltz, Robert J. Mayer, Al B. Benson, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Alan P. Venook, Shuji Ogino, Edward L. Giovannucci, Charles S. Fuchs

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

124 Scopus citations

Abstract

We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

Original language	English (US)
Journal	Journal of the National Cancer Institute
Volume	107
Issue number	1
DOIs	https://doi.org/10.1093/jnci/dju345
State	Published - Jan 1 2015

Funding

This work was supported by the National Cancer Institute, National Institutes of Health (P50 CA127003 and K07 CA148894 to KN), the Conquer Cancer Foundation of the American Society of Clinical Oncology (to KN), the Damon Runyan Cancer Research Foundation (to ATC), and the Pharmacia and Upjohn Company, now Pfizer Oncology. The research for CALGB 89803 was also supported, in part, by grants from the National Cancer Institute, National Institutes of Health (CA31946) to the Alliance for Clinical Trials in Oncology (Monica Bertagnolli, MD, Chairman) and to the Alliance Statistics and Data Center (Daniel J. Sargent, PhD, CA33601).

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jnci/dju345

Cite this

Ng, K., Meyerhardt, J. A., Chan, A. T., Sato, K., Chan, J. A., Niedzwiecki, D., Saltz, L. B., Mayer, R. J., Benson, A. B., Schaefer, P. L., Whittom, R., Hantel, A., Goldberg, R. M., Venook, A. P., Ogino, S., Giovannucci, E. L., & Fuchs, C. S. (2015). Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. Journal of the National Cancer Institute, 107(1). https://doi.org/10.1093/jnci/dju345

@article{efa5427f676b49c08041df4b2a57d5bf,

title = "Aspirin and COX-2 inhibitor use in patients with stage III colon cancer",

abstract = "We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.",

author = "Kimmie Ng and Meyerhardt, {Jeffrey A.} and Chan, {Andrew T.} and Kaori Sato and Chan, {Jennifer A.} and Donna Niedzwiecki and Saltz, {Leonard B.} and Mayer, {Robert J.} and Benson, {Al B.} and Schaefer, {Paul L.} and Renaud Whittom and Alexander Hantel and Goldberg, {Richard M.} and Venook, {Alan P.} and Shuji Ogino and Giovannucci, {Edward L.} and Fuchs, {Charles S.}",

note = "Publisher Copyright: {\textcopyright} The Author 2014. Published by Oxford University Press.",

year = "2015",

month = jan,

day = "1",

doi = "10.1093/jnci/dju345",

language = "English (US)",

volume = "107",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "1",

}

Ng, K, Meyerhardt, JA, Chan, AT, Sato, K, Chan, JA, Niedzwiecki, D, Saltz, LB, Mayer, RJ, Benson, AB, Schaefer, PL, Whittom, R, Hantel, A, Goldberg, RM, Venook, AP, Ogino, S, Giovannucci, EL & Fuchs, CS 2015, 'Aspirin and COX-2 inhibitor use in patients with stage III colon cancer', Journal of the National Cancer Institute, vol. 107, no. 1. https://doi.org/10.1093/jnci/dju345

TY - JOUR

T1 - Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

AU - Ng, Kimmie

AU - Meyerhardt, Jeffrey A.

AU - Chan, Andrew T.

AU - Sato, Kaori

AU - Chan, Jennifer A.

AU - Niedzwiecki, Donna

AU - Saltz, Leonard B.

AU - Mayer, Robert J.

AU - Benson, Al B.

AU - Schaefer, Paul L.

AU - Whittom, Renaud

AU - Hantel, Alexander

AU - Goldberg, Richard M.

AU - Venook, Alan P.

AU - Ogino, Shuji

AU - Giovannucci, Edward L.

AU - Fuchs, Charles S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

AB - We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84926518325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926518325&partnerID=8YFLogxK

U2 - 10.1093/jnci/dju345

DO - 10.1093/jnci/dju345

M3 - Article

C2 - 25432409

AN - SCOPUS:84926518325

SN - 0027-8874

VL - 107

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 1

ER -

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this